News Novartis reveals more data behind Pluvicto expansion bid Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.
News FDA's ODAC delivers one loss, one win for AstraZeneca The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
News Denying prostate cancer screening 'no longer rational' A German study has stoked debate about the merits of screening for prostate cancer, which is lagging behind breast cancer screening in Europe.
News Incyte breaks new ground in anal cancer with EU approval Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.
News Change of heart as NICE backs prostate cancer drug Talzenna Thousands of men with prostate cancer will be offered a new treatment, Pfizer's Talzenna, after NICE made an about-turn on the drug.
News NICE relents, ending postcode access to prostate cancer drug Men in England with high-risk prostate cancer will soon be able to get treatment with a drug available in Scotland and Wales for almost three years.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
